Skip to content

Released May 15, 2017, after the close

10-Q filed May 15, 2017, 45 days after period end · 0001564590-17-011043

Q1 2017 · 10-Q
Revenue$1.03M−22.3% vs Q1 2016±0.0% vs Q4 2016
Net Income-$10.13MN/M vs Q1 2016N/M vs Q4 2016
EPS Diluted-$0.24N/M vs Q1 2016N/M vs Q4 2016
Operating Income-$9,971,000N/M
Operating Cash Flow-$7,455,000N/M
Free Cash Flowderived-$7,610,000N/M
Margins · derived
Operating margin-970.9%−372.1 pt vs Q1 2016
Net margin-986.0%−352.3 pt vs Q1 2016

What the release said

The release

Same quarter

MetricQ1 2017Q1 2016Q1 2015Q1 2014
Revenue$1.03M$1.32M——
Net Income-$10.13M-$8.38M-$7.88M-$6.98M
EPS Diluted-$0.24-$0.29-$0.38-$0.34

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Fate Therapeutics Inc · CIK 1434316 · Engraved from SEC EDGAR